Domingo-Domenech Research


Name: Josep Domingo-Domenech, MD PhD
Position: Professor

233 S 10th Street
Philadelphia , PA 19107

Telephone: 215-955-3404
Alt text

The Domingo-Domenech laboratory main focus is to assess the molecular and cellular mechanisms contributing to the pathogenesis of aggressive lethal cancer, mainly in genitourinary tumors (i.e. prostate and bladder cancers). We use in vitro and in vivo mouse experimental models together with patient datasets to functionally dissect the genes and pathways involved in the initiation, therapy response and metastasis of cancer. In addition, we are investigating the cellular heterogeneity of tumors to identify the molecular pathways that allow specific population of cells (i.e. cancer stem cells) survive standard therapies. The research program comprehensively integrates experimental data using computational tools to develop novel anti-tumor therapeutic approaches and determine new molecular surrogates of clinical outcome.

The Domingo-Domenech lab is a multi-disciplinary group encompassing cancer biologists, molecular biologists, computational biologist, biochemists, urologists and medical oncologist. We collaborate with other research groups both nationally and internationally.  The lab is currently funded by grants from the NIH/NCI, Department of Defense and research foundations.

HomeImage Research projects of the Domingo-Domenech laboratory include: A) Computational studies of public genomic available datasets; B) Examination of molecules of interest in human tumor samples (i.e. Immunohistochemistry, FISH); C) Molecular dissection of actionable mechanisms (i.e. functional genomics); D) Development of clinically significant mouse (GEM) and human (PDX and organoid) experimental system models; and E) Testing of novel experimental therapeutic approaches in pre-clinical models.

Research Projects

  1. Dissect the role of master regulator transcription factor (i.e. GATA2, MITF, etc…) signaling network in lethal prostate cancer.
  2. Molecular characterization of tumor heterogeneity (i.e.Cancer Stem Cells) in prostate cancer and other tumor types.
  3. Development of circulating tumor cell-patient derived xenograft (CTC-PDX) and -organoid (CTC-Org) platforms in prostate and bladder cancer, among other tumor types.
  4. Discover novel targetable pathways of bladder cancer progression to cisplatin based chemotherapy.
  5. Molecular and functional characterization of prostate and bladder cancer exosomes.